We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 12.00 | 380,078 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 11.50 | 12.50 | 12.00 | 12.00 | 12.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics,resins,elastomers | 2.18M | -2M | -0.0323 | -3.72 | 7.45M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:10:18 | O | 75,000 | 12.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/4/2024 | 09:49 | ALNC |  RUA Life Sciences expects flat annual revenue on strong second half |
| 05/4/2024 | 08:30 | UK RNS | RUA Life Sciences PLC Business Update |
| 30/1/2024 | 07:00 | UK RNS | RUA Life Sciences PLC Change of Auditor |
| 29/1/2024 | 07:00 | UK RNS | RUA Life Sciences PLC Directorate Change |
| 21/12/2023 | 17:30 | UKREG | RUA Life Sciences PLC Holding(s) in Company |
| 21/12/2023 | 12:00 | UKREG | RUA Life Sciences PLC Holding(s) in Company |
| 20/12/2023 | 17:57 | ALNC | EARNINGS AND TRADING: Half-year loss widens at Triad as revenue falls |
| 20/12/2023 | 07:00 | UKREG | RUA Life Sciences PLC Heart Valve Leaflet Material - Testing Update |
| 19/12/2023 | 16:30 | UKREG | RUA Life Sciences PLC Holding(s) in Company |
| 18/12/2023 | 17:34 | UKREG | London Stock Exchange Notice N06/23 - Restoration of trading |
Rua Life Sciences (RUA) Share Charts1 Year Rua Life Sciences Chart |
|
1 Month Rua Life Sciences Chart |
Intraday Rua Life Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/4/2024 | 22:10 | RUA Life Sciences - Elast-Eon Enabled MedTech | 3,589 |
| 06/4/2024 | 09:54 | purple the twat is a nasty TROLL | 24 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-15 16:10:19 | 12.20 | 75,000 | 9,150.00 | O |
| 2024-04-15 15:07:08 | 12.18 | 12,287 | 1,495.94 | O |
| 2024-04-15 14:58:40 | 12.05 | 53,750 | 6,474.19 | O |
| 2024-04-15 14:57:02 | 12.02 | 50,000 | 6,010.00 | O |
| 2024-04-15 14:47:27 | 12.05 | 4,242 | 510.95 | O |
| Top Posts |
|---|
Posted at 15/4/2024 09:20 by Rua Life Sciences Daily Update Rua Life Sciences Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker RUA. The last closing price for Rua Life Sciences was 12p.Rua Life Sciences currently has 62,060,272 shares in issue. The market capitalisation of Rua Life Sciences is £7,447,233. Rua Life Sciences has a price to earnings ratio (PE ratio) of -3.72. This morning RUA shares opened at 12p |
Posted at 08/4/2024 09:41 by rivaldo Cavendish retain their 25p price target in their update this morning (with a £7.8m m/cap at 12.5p).Brief extracts: "Strong strategic progress RUA Life Sciences has provided a business update for the year to March 2024, noting revenue shortfalls experienced in H1/24 have been made up by a strong second half. Revenues for the year are therefore expected to be in-line with our forecast £2.2m, while the company notes gross margin will exceed our forecasts, with operating costs remaining tightly controlled. RUA Life Sciences closed FY24 with cash of c£4.0m versus our £3.3m estimate. The company reports significant progress towards its goal of near-term profitability through growing its contract manufacturing business, noting strong progress with a ‘global enterprise’. Finally, RUA has completed a Material Transfer Agreement with a global Heart Valve company covering its composite heart valve material. We believe this update demonstrates excellent progress against the company’s revised strategy." "Strategy – As noted with its successful fundraise in December 2023, RUA’s revised strategy will seek to grow its Contract Manufacturing business, generating long-term contract revenues, explore third-party funding for its vascular graft portfolio and pursue licence opportunities for its composite heart valve material. We believe this business update demonstrates strong progress against this strategy. - Investment thesis – We believe the combination of established revenues with growth potential and the option to deliver significant returns through the disruption of established billion-dollar global cardiovascular markets makes RUA Life Sciences an attractive investment opportunity. RUA now aims to turn profitable in the short term and has adopted a strategy to deliver earlier returns on its Vascular and Structural Heart investments." |
Posted at 05/4/2024 08:59 by parob Very good update imo. Plenty of cash/time to get sone commercial deals over the line. Speculation alone could drive this higher. Business Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.TradingThe first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.Cash PositionStrong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.Business DevelopmentSignifica |
Posted at 26/3/2024 09:59 by hedgehog11 Thanks burtond1, I always enjoy a feel good read, but someone at RUA must write for Total Market Solutions.My favourite quote; "The strategy is showing signs of paying off, with RUA’s Contract Manufacture, Structural Heart and Vascular branches closing in on deals that promise significant longer-term cash generation and profitability." And I must of missed a few RNS' "Another Contract Manufacture customer ‘is expected to submit a bid request in the next few months at a value of around £500,000." If only bid requests earned income. "The company hopes to double its Contract Manufacture business by continuing to convert sales discussions into formal bid processes." When? "RUA’s Vascular division is seeking third party funding for an advanced project that has attracted interest from original equipment manufacturers, and early commercial sales. All the conditions are in place for the commencement of the regulatory testing regime:" interest in what from who? Joking aside, I've not paid much attention recently but these assertions need backing up and I'm pretty sure the correct place to do that would be an RNS! This article is a typical RUA RNS with a positive spin on it. There's no doubt what is says is what everyone is now hoping for. The doubt is not in the products. It is whether they are really is as good as the claims and the ability of the company to get a return from it. A balanced article would have highlighted some of the challenges and failures RUA are experiencing. The frustration is, that if the tide does turn for RUA, the returns from this point will be pretty impressive. |
Posted at 18/12/2023 13:45 by bones Cavendish fair value of 25p is stated to be without giving any value to Vascular and Structural Heart, so just based on prospects for existing profitable business growth from Contract Manufacturing and Biomaterials.The depressed share price has been almost entirely down to the market pricing in a worst case scenario of running short of money and a scramble to raise finance. To be fair, I think the raise has been in the pipe for a few months and it could have been much worse compared to others. RUA gets credit for actually having its two profit making businesses in place. It wasn’t a one trick pony with everything dependent upon a trial result. Lots more shares in play now so it’s going to take some good developments to recover the recent share prices but I don’t see why at least 20p can’t come soon. The placing price has temporarily wrecked sentiment. |
Posted at 08/12/2023 09:19 by the surgeon If Brown had not exaggerated the merits of his vascular grafts over the opposition we in all probability would not have had to do trials in the first place since it would have been just an alternative in the field. But hubris and stupidity resulted in having to do trials. The time for boasting that’s RUA’s product was superior to those already on the market. Revenues would have been accrued and RUA would have a share price over £1.50. If RUA is just going to receive royalties from a heart valve which is years away from being on the market do not expect much in the rise in the share price and certainly not back to the £1.50 level. I hope I am wrong but I feel the trials of the vascular grafts must be done to bring in future revenue. We are still talking about at three years assuming the trials are successful. I know I am painting a pessimistic picture but realism must prevail. I could be wrong and I wish all those holding significant holdings the best of luck. |
Posted at 24/11/2023 11:01 by drradcliffe What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.From their note 21/11/23: "Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update." "Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive." Does this mean the market itself wasn't expecting this trading update? I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders? If you are going to arrange a small placing, the last thing you want is a highly volatile share price. |
Posted at 21/11/2023 10:27 by nimbo10 Share price brought to it's knees on rights issue worries, with that now gone, back to normal valuations and to top it quicker time to profitability.Also like statement of substantial upside from yesterday's rns. If Bill is to be believed. Sicilian no chance of fund raise as market will loose complete trust in management after yesterday's statement. "The limiting factor however is the cost of capital placed upon RUA because of the depressed share price. Not only would dilution relate to the interest in the Vascular project but the substantial upside potential from both RUA Contract Manufacture and RUA Structural Heart would be limited for current shareholders" |
Posted at 21/11/2023 10:19 by edmonda Strategy Update, sticking to its objectives - new note from Equity Development (link here: In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update. In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive. RUA Contract Manufacture, the contract manufacturer of medical devices using implantable fabrics with a biocompatible Elast-Eon coating, is responding to a formal bid request that could result in around £2m in revenues, with much of that recuring on an annual basis. Thus, RUA’s board’s objective of doubling the scale of the contract manufacturing business in the medium term is on track. |
Posted at 20/11/2023 11:51 by langland A few quick notes on today's RNS.Obviously I am happy to see the progress on the 3 fronts after the dire share price performance so far this year. CM Turnover on track to double though no deals signed yet but it does seem to vindicate previous Board comments. HV 'Rather than incur the full cost of developing a valve directly, our strategic focus is now to accelerate the commercial potential of RUA Structural Heart by making the composite available to the heart valve industry for incorporation into next generation valves. The Company expects to shortly formalise an agreement to provide composite material to a large heart valve company for its own testing and now that an attractive data pack is available on the composite, RUA intends to broaden this further through the industry' I thought it worth repeating the final paragraph because it highlights 2 things. First, a major player (think Edwards) will shortly formalise agreement to test the HV with possibility of some upfront cash (though not stated). Secondly, the possibility that the HV technology could be thrown open to whole industry. I can't help but think that the likes of Edwards and Medtronic won't like that. VD It depends how any deal is structured but a mixture of flexibility on % and money upfront to cover back costs. And finally we need to remember that RUA is absolutely dwarfed by all the companies it is speaking to. So, what price a takeout by a corporation keen on safeguarding RUA IP from competitors? |
Posted at 28/7/2023 17:28 by bones Langland, just caught up with your posts (2912, 2916, etc). I agree that at this stage it is looking like a case of working out what needs selling off (if possible) to get some cash and stability back on the rails. As you suggest, the sale of the vascular division might work if someone better capitalised can take on the project and its assets.RUA says with just the pilot plant operational, the business would be worth around £25M but of course a sale now would be pre-trials so any buyer would want a big discount to cover the expected costs of trials plus a risk premium to cover the possibility of trial problems. Maybe £10M then for the whole project as it stands? That would still be a clear £5M profit on the project over its development period of 5 years to date. Given that the addressable market is large, £10M might be worth paying by someone for the huge upside to them if all goes well. The outcome would be valuable cash for RUA and a future Elasteon royalty stream from any future sales of grafts by the new owner. Some staff would also leave with the business too saving on those costs. The safety of cash in hand and the removal of the millstone of trials uncertainties and costs from the neck of RUA would be a blessing for the share price. Will the egos of the board even contemplate this? This was the basis of the reboot in 2018 after all and a lot has been achieved on a small budget. They should do it though. Not only because “needs must” right now but it would free up the group to concentrate on its core licensing side. It sounds as though there are some breakthroughs occurring in the heart valve and heart leaflet technology and staff efforts could better be directed towards that area having been freed of the burden that Vascular has become. Being free of dealing with that monster called the FDA (a common graveyard for small UK Med-Techs and pharmas) would also be a relief in my opinion. Would Corcym be a problem (if they were not the buyer)? I don’t see why since they get nothing from the products if they are not trialled and marketed. Businesses make things work for them. The group has done wonders with what it has achieved on a relative pittance in terms of its graft and HV technologies but that’s when to hive off the work to the bigger boys where the big bucks are needed and available. Alternatively, if it is felt that the vascular breakthrough is worth persevering with, then sell the apparently ready made contract manufacturing business which seems to be worth a good £10M according to the directors based on an EBITDA multiple and it is already a profitable enterprise. That should appeal to more buyers? This would mean the R&D activities would have to once again buy in the facilities from the contract manufacturing division that would now be a third party (as it was prior to the buyout of RUA Medical but at least RUA would continue to earn royalties on any elasteon being used in the products. Again, savings on staff that leave with the business would be a benefit. That’s two possibilities there without necessarily relying on a placing (if feasible). Surely the board have been looking at these options over the last year given that the 2022 webinar presentations made a point of highlighting the valuations of each business division? I took that to mean they were all potentially available for sale for anyone looking in and not just to make shareholders feel better about the wide discount in share price to those values. Time is now short so the board needs to be radical rather than worrying about pride that maybe their grand ideas have also come up short. Not easy but running businesses never is but maybe now is the time for the board to prove themselves and right this ship. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
